Calls for papers
-
According to Gossamer Bio, the Phase 3 PROSERA trial of its seralutinib dry powder inhaler in patients with pulmonary arterial hypertension missed its primary endpoint of change in 6-minute walk distance from baseline. The company… Read more . . .
-
Iconovo announced that it has signed a letter of intent with CDMO Lonza related to development of spray dried formulation of inhaled biologics. The companies announced in January 2025 that Lonza would develop spray dried… Read more . . .
-
According to Savara, the FDA has accepted the company’s BLA for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis. In March 2025, Savara announced that it had completed a rolling BLA submission… Read more . . .
-
Cyrano Therapeutics has announced that the Phase 2 FLAVOR trial of CYR-064 intranasal theophylline soft-mist spray for the treatment of hyposmia (loss of smell) following viral infection did not demonstrate any safety or tolerability concerns,… Read more . . .
-
UK-based Essential Pharma announced that it has acquired the rights to market Bayer’s Ventavis iloprost trometamol inhalation solution for the treatment of primary pulmonary hypertension in all markets except for the US and Russia. Essential… Read more . . .
-
Experic, which offers a range of development and manufacturing services for DPIs, has announced the appointment of former Catalent Drug Delivery Solutions General Manager Matthew Mollan as Chief Executive Officer. According to the company, previous… Read more . . .
-
Iliad Biotechnologies announced that it has raised $115 million in a Series B financing to support continued development of the company’s BPZE1 intranasal vaccine against pertussis (whooping cough). The company said that it intends to… Read more . . .
-
Qnovia announced that a Phase 1 trial of RespiRx inhaled nicotine, which is delivered via a handheld nebulizer, demonstrated that the nebulized formulation produced a Tmax comparable to cigarettes with lower plasma exposure. Qnovia had… Read more . . .
-
MannKind Corporation has announced the initiation of the Phase 2 INHALE-1ST trial of Afrezza inhaled dry powder insulin in children aged 10 and over who have recently received a diagnosis of Type 1 diabetes. The study… Read more . . .
-
According to Krystal Biotech, the FDA has granted regenerative medicine advanced therapy (RMAT) designation to the company’s KB707 inhaled gene therapy for the treatment of non-small cell lung cancer. The company notes that the designation… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA